Upstream Bio Analyst Price Targets - Benzinga

Upstream Bio Inc

UPBNASDAQ

Trade with Public

Trade with Public

$5.36

0.193.68%

가까이에: Sep 25, 5:00 PM EST

$5.34

-0.02-0.37%

시간외: 6:11 PM EST

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

Upstream Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Upstream Bio (UPB).

Price Target Range — 5 Quarters

Analyst Consensus — 9 Analysts

7Buy

2Hold

Consensus RatingOutperform# Analysts9Avg. Consensus PT$36Upside to Avg. PT+576.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 2, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$36
Aug 14, 2026	JP Morgan	Tessa Romero	PT Raise	Neutral	$8→$9
Aug 12, 2026	Truist Securities	Danielle Brill	PT Cut	Buy	$43→$25
Jun 12, 2026	JP Morgan	Tessa Romero	Downgrade	Overweight→Neutral	$35→$8
Jun 3, 2026	HC Wainwright & Co.	Matthew Caufield	Initiate	Buy	$36
May 14, 2026	Mizuho	Joseph Catanzaro	PT Cut	Outperform	$51→$50
Mar 27, 2026	Evercore ISI Group	Cory Kasimov	Downgrade	Outperform→In-Line	$40→$15
Dec 18, 2025	Mizuho	Joseph Catanzaro	Initiate	Outperform	$51
Dec 2, 2025	LifeSci Capital	—	Initiate	Outperform	$43
Nov 18, 2025	Evercore ISI Group	Cory Kasimov	Initiate	Outperform	$40
Oct 14, 2025	Truist Securities	Danielle Brill	Initiate	Buy	$47
Nov 5, 2024	JP Morgan	Tessa Romero	Initiate	Overweight	$38
Nov 5, 2024	William Blair	Matt Phipps	Initiate	Outperform	—
Nov 5, 2024	TD Cowen	Yaron Werber	Initiate	Buy	—
Nov 5, 2024	Piper Sandler	Yasmeen Rahimi	Initiate	Overweight	$75

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Upstream Bio, Maintains $36 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Upstream Bio (NASDAQ:UPB) with a Buy and maintains $36 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9

JP Morgan analyst Tessa Romero maintains Upstream Bio (NASDAQ:UPB) with a Neutral and raises the price target from $8 to $9.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Upstream Bio, Lowers Price Target to $25

Truist Securities analyst Danielle Brill maintains Upstream Bio (NASDAQ:UPB) with a Buy and lowers the price target from $43 to $25.

Benzinga Newsdesk

PRO
JP Morgan Downgrades Upstream Bio to Neutral, Lowers Price Target to $8

JP Morgan analyst Tessa Romero downgrades Upstream Bio (NASDAQ:UPB) from Overweight to Neutral and lowers the price target from $35 to $8.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Initiates Coverage On Upstream Bio with Buy Rating, Announces Price Target of $36

HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Upstream Bio (NASDAQ:UPB) with a Buy rating and announces Price Target of $36.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Upstream Bio, Lowers Price Target to $50

Mizuho analyst Joseph Catanzaro maintains Upstream Bio (NASDAQ:UPB) with a Outperform and lowers the price target from $51 to $50.

Benzinga Newsdesk